Independent panel set up to advise on specialist NHS treatment for Wales

22 June 2008

Following a review into the Health Commission Wales, a new independent panel made up of members of the general public will be set up to decide which specialist treatments will be provided by the National Health Service, Health Minister Edwina Hart has announced.

The recommendation for such a body forms part of the conclusions of the review, commissioned by the Health Minister last October, into the role and remit of the HCW. The review was undertaken by Mansel Aylward, chairman of the Wales Centre for Health.

Ms Hart pointed out that the new panel would increase patient and public engagement in what was a difficult decision-making process. She said: "undoubtedly, commissioning treatment for individual patients rests at the cutting edge of medical science, but these decisions also draw on issues of morality and our shared understanding of what the NHS can be expected to provide as well as those of medicine and money."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight